AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022
AcelRx Pharmaceuticals (Nasdaq: ACRX) will release its Q1 2022 financial results before the market opens on May 16, 2022. A live webcast and conference call hosted by management will begin at 8:30 a.m. ET to discuss the financial results and provide business updates. The webcast can be accessed via their website. AcelRx specializes in innovative therapies for medically supervised settings, with products including DSUVIA and several investigational candidates.
- AcelRx has an approved product, DSUVIA, in the U.S. for severe acute pain management.
- DSUVIA and Zalviso are both approved in Europe, expanding market reach.
- The webcast will provide insights into the company's financial performance.
- None.
HAYWARD, Calif., May 9, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results before market open on Monday, May 16, 2022. AcelRx management will host a live webcast and conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on May 16, 2022 to discuss the financial results and provide an update on the company's business.
The webcast is accessible by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be accompanied by a slide presentation. A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com.
Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers, or (412) 902-4204 for international callers.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and several product candidates. The product candidates include: Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S. being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings; two pre-filled, ready-to-use syringes of ephedrine and phenylephrine licensed for the U.S. from Aguettant; Niyad™, a regional anticoagulant for the extracorporeal circuit; and LTX-608, for the potential treatment of COVID-19, disseminated intravascular coagulation, acute respiratory distress syndrome and acute pancreatitis. DZUVEO and Zalviso are both approved products in Europe.
For additional information about AcelRx, please visit www.acelrx.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-first-quarter-2022-financial-results-call-and-webcast-on-may-16-2022-301543167.html
SOURCE AcelRx Pharmaceuticals, Inc.
FAQ
When will AcelRx Pharmaceuticals release its Q1 2022 financial results?
What time is the AcelRx conference call for Q1 2022 financial results?
How can I access AcelRx's financial results webcast?
What is DSUVIA and its significance for AcelRx?
Is AcelRx Pharmaceuticals publicly traded?
